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Abstract: Microorganisms can colonize a wide variety of medical devices, putting patients 
in risk for local and systemic infectious complications, including local-site infections, 
catheter-related bloodstream infections, and endocarditis. These microorganisms are able  
to grow adhered to almost every surface, forming architecturally complex communities 
termed biofilms. The use of natural products has been extremely successful in the discovery 
of new medicine, and mushrooms could be a source of natural antimicrobials. The present 
study reports the capacity of wild mushroom extracts to inhibit in vitro biofilm formation 
by multi-resistant bacteria. Four Gram-negative bacteria biofilm producers (Escherichia 
coli, Proteus mirabilis, Pseudomonas aeruginosa, and Acinetobacter baumannii) isolated 
from urine were used to verify the activity of Russula delica, Fistulina hepatica, Mycena 
rosea, Leucopaxilus giganteus, and Lepista nuda extracts. The results obtained showed that 
all tested mushroom extracts presented some extent of inhibition of biofilm production. 
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Pseudomonas aeruginosa was the microorganism with the highest capacity of biofilm 
production, being also the most susceptible to the extracts inhibition capacity (equal or 
higher than 50%). Among the five tested extracts against E. coli, Leucopaxillus giganteus 
(47.8%) and Mycenas rosea (44.8%) presented the highest inhibition of biofilm formation. 
The extracts exhibiting the highest inhibitory effect upon P. mirabilis biofilm formation 
were Sarcodon imbricatus (45.4%) and Russula delica (53.1%). Acinetobacter baumannii 
was the microorganism with the lowest susceptibility to mushroom extracts inhibitory 
effect on biofilm production (highest inhibition—almost 29%, by Russula delica extract). 
This is a pioneer study since, as far as we know, there are no reports on the inhibition of 
biofilm production by the studied mushroom extracts and in particular against multi-resistant 
clinical isolates; nevertheless, other studies are required to elucidate the mechanism of action. 
Keywords: clinical isolates; biofilm; wild mushroom extracts; multi-resistant; cytotoxicity 
 
1. Introduction 
Antimicrobial resistance (AMR) is a serious threat to public health. The level of AMR, especially 
multidrug resistance, is increasing in Europe, leading to high healthcare costs associated with high 
morbidity and mortality levels [1]. 
Multi-resistance is considered to be a key indicator of problematic bacterial strains because it 
constrains empirical treatment regimens and reduce the options of appropriate treatments [2]. This 
situation is considered to be an infection control priority to manage patient mortality and limit the 
spread of multi-resistant strains. 
Microorganisms can colonize a wide variety of medical devices, putting patients in risk for local 
and systemic infectious complications, including local-site infections, catheter-related bloodstream 
infections, and endocarditis [3]. Bacteria, such as Escherichia coli, Pseudomonas aeruginosa, Klebsiella 
pneumoniae, Proteus mirabilis, MRSA (methicillin-resistant Staphylococcus aureus) and Enterococcus 
spp., are involved in urinary infections with the highest biofilm production rates [4–8]. According  
to the Annual Epidemiological Report of 2013, Acinetobacter baumannii also presents, in Portugal, a 
higher prevalence (4.5%) than the European Union medium (1.9%) in urinary infections of catheterized 
patients in Health Intensive Care Unities [1]. 
These bacteria are able to grow adhered to almost every surface, forming architecturally complex 
communities termed biofilms [9–12]. Encased in a complex polysaccharide matrix produced by the 
bacteria themselves, a biofilm permits to protect the bacteria against antibiotics, being the cause of 
many recalcitrant infections. 
In the last decade, several strategies to control biofilm growth on medical devices have been suggested, 
including the use of topical antimicrobial ointments, minimizing the length of time of catheterization, 
using catheters provided with a surgically implanted cuff [13], and coating the catheter lumen with 
antimicrobial agents [14–22]. However, these antimicrobial-loaded catheters may pose several limitations, 
including the rapid release of the adsorbed antibiotic in the first hours after implantation and, as a 
result, a relatively short persistence of antibacterial action [23]. The risk of emerging multidrug-resistant 
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pathogens is continuously growing due to the extensive use of antibiotics both in prophylaxis and 
long-term therapy. Microorganisms growing in a biofilm are much more resistant to antimicrobial 
agents than planktonic cells and hence treatment of biofilm contaminated surfaces with conventional 
antimicrobials may fail as it is known that it takes >1000 times more antibiotics to kill biofilm cells 
than to kill planktonic cells [9]. 
The use of natural products has been extremely successful in the discovery of new medicine [24]. 
According to Harvey [24], the access to biodiversity is fundamental to expanding the range of natural 
products to be used in the search for new drugs. In this context, mushrooms, which remain unexplored 
in this area, might be a valuable resource in the search of new bioactive extracts/compounds to inhibit 
biofilm production. 
In fact, mushrooms could be a source of natural antibiotics. The extracts of some species, including 
Laetiporus sulphureus [25], Ganoderma lucidum [26], and Lentinus edodes [27] have already 
demonstrated antibacterial activity. Furthermore, Alves et al. [28], demonstrated that Fistulina 
hepatica, Ramaria botrytis, and Russula delica extracts were promising against multi-resistant 
microorganisms namely MRSA, Escherichia coli and Proteus mirabilis. This activity was mainly 
attributed to phenolic acids present in the methanol: water extracts [29]. Additionally, Jagani et al. [30] 
have shown that phenol and natural phenolic compounds cause a significant reduction in biofilm 
formation by P. aeruginosa. Soković et al. [31] described anti quorum sensing activity of Agaricus 
blazei hot water extract in the same bacteria. In addition, the effects of Lentinus edodes extract and 
purified fractions on human oral pathogens in biofilm state have been described [32]. 
Therefore, the present study reports the capacity of wild mushroom metanol:water extracts to inhibit 
in vitro biofilm formation in multi-resistant bacteria isolated from clinical specimens. Being the 
mentioned extracts rich in phenolic compounds [29], these natural molecules can provide an excellent 
alternative for inhibition of biofilm production. Furthermore, the toxicity of the tested extracts was also 
assessed in order to guarantee the safety of their use. As far as we know, this is the first study on the 
inhibition of biofilm production by the tested mushroom extracts and in particular against multi-resistant 
clinical isolates. 
2. Results and Discussion  
Data available in Table 1 show that, in general, all tested mushroom extracts presented some extent 
of inhibition of biofilm production according the different tested microorganisms. Furthermore, none 
of the extracts, at the tested concentrations (up to 20 mg/mL), have shown toxicity against a primary 
culture of porcine liver cells (PLP2; the GI50- concentration responsible for inhibition of 50% of the 
cells net growth- of the positive control, ellipticine was 3.8 ± 0.5 μM). 
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Table 1. Effect of sub-MIC (minimal inhibitory concentrations) of wild mushroom extracts 
in the biofilm production by different clinical isolates (Mean ± SD; n = 3). 
Mushroom 
Average Production Inhibition of Biofilm (%)  
P. aeruginosa  E. coli A. baumannii P. mirabilis  
L. nuda 55.99 ± 1.13 ª 22.89 ± 1.53 c 14.22 ± 2.52 b 39.73 ± 2.17 b 
L. giganteus  56.79 ± 8.78 ª 47.84 ± 0.93 ª 15.12 ± 0.58 b 41.72 ± 6.53 ab 
M. rosea  53.36 ± 8.02 ª 44.88 ± 0.68 ª 16.08 ± 1.05 b 40.24 ± 2.08 ab 
R. delica 57.35 ± 5.01 ª 29.37 ± 4.95 bc 28.59 ± 0.70 ª 60.31 ± 1.20 a 
S. imbricatus  57.49 ± 6.63 ª 32.41 ± 5.86 b 17.15 ± 1.97 b 49.97 ± 2.53 ab 
In each column different letters mean significant differences (p < 0.05). 
Pseudomonas aeruginosa (resistant to cephalosporins, amoxicillin/clavulanic acid, fluoroquinolonas 
and trimethoprim sulfaxonazol) was the microorganism with highest capacity of biofilm production 
(Figure 1) and was the microorganism that exhibited the highest inhibition percentage (equal or higher 
than 50%) of biofilm formation by the different extracts at the tested concentration, without significant 
statistical differences (p < 0.05) (Figure 2). 
Other authors [30,33,34] also reported excellent results of different pure compounds present  
in natural products (usnic acid, terpenes and various phenolic compounds) in the inhibition of biofilm 
production by P. aeruginosa. Particularly, Jagani et al. [30] demonstrated the potential of phenol (80.9%) 
and natural phenolic compounds (e.g., tannic acid—78.1%, eppigallocatechin—69.9%, catechin—67.5%) 
to inhibit biofilm of the mentioned bacteria. 
Figure 1. Absorbance values of the biofilm formed in the presence of various mushroom extracts. 
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Figure 2. Percentage of inhibition of biofilm production exerted by mushroom extracts 
upon different clinical isolates. 
 
 
In addition, Borges et al. [35] demonstrated that flavonoids (ferulic and gallic acid) inhibited the 
ability of biofilm production in P. aeruginosa, fact that the authors related to the interference in cell 
motility and physico-chemical changes in the cell surface. 
Considering that the extracts tested in the present work possess phenolic compounds (e.g., phenolic 
acids and a few flavonoids, Table 2), these molecules could be responsible for the observed properties. 
Moreover, it should be highlighted that these results are very relevant since P. aeruginosa is one of  
the problematic microorganisms in hospital environment, being highly involved in infections related 
with health care (HAI) due to multi-resistance and high capacity to produce biofilm. According to 
Annual Epidemiological Report of 2013 [1], P. aeruginosa (12.5%) is among the five microorganisms 
most isolated from acquired urinary tract infections in patients of European Health Intensive Care 
Unities. Furthermore, this bacterium is cited for its high resistance to different antibiotic groups 
(aminoglycosides, fluoroquinolones and carbapenems [1], also observed for the clinical isolate used 
herein for fluoroquinolones. 
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According to Hancock et al. [36], ellagic acid and tannic acid potentiate the action of the substance 
thioridazine known as an inhibitor of efflux pumps, producing a greater anti-biofilm activity in E. coli. 
Vikram et al. [37], tested the capacity of flavonoids to inhibit biofilm of E. coli O157:H7, and quercetin 
showed to be the most potent one. Nevertheless, flavonoids are not commonly found in mushrooms, 
being phenolic acids the most abundant phenolic compounds [38]; Table 2). Borges et al. [35] found 
that ferulic and gallic acids showed inhibitory capacity on the production of biofilms in E. coli; 
probably the results obtained for E. coli in the present work (Table 1) might be due to the presence of 
phenolic compounds in the tested extracts (Table 2), but also other non-identified compounds (see for 
example Leucopaxillus giganteus results in Table 2). Among the five tested extracts against E. coli, 
Leucopaxillus giganteus (47.8%), and Mycenas rosea (44.8%) presented the highest significant  
(p < 0.05) biofilm inhibition. Another important aspect is that the E. coli strain used in the present 
work is a clinical isolate and not a collection microorganism as the one used by Vikram et al. [37]. The 
extracts exhibiting the best inhibitory effect upon P. mirabilis (resistant to fluoroquinolones, ampicillin 
and cephalosporins) biofilm formation were Sarcodon imbricatus (45.4%) and Russula delica (53.1%). 
In fact, the inhibition effect of the tested mushroom extracts upon Proteus mirabilis was lower than the 
ones obtained for P. aeruginosa (Figure 2), but still relevant, due to the high capacity of P. mirabilis  
to produce biofilm in urinary catheters an due to its high antibiotic resistance. Some microorganisms 
such as P. mirabilis change pH values by producing urease, which hydrolyses urea to ammonia that 
increases pH value, promoting the precipitation of minerals, which in turn are deposited on catheters 
causing mineral inlays and stimulating biofilms production [39]. No study was found reporting the activity 
of pure phenolic compounds or natural extracts on biofilm formation. 
Acinetobacter baumannii was the microorganism with the lowest susceptibility to mushroom 
extracts inhibitory effect on biofilm production (Figure 2); Russula delica extract inhibited biofilm 
production by almost 29%, showing the best performance among all the extracts (p < 0.05) (Figure 1). 
Being this microorganism extremely resistant to different groups of commercial antibiotics, results 
obtained are promising in the control of biofilm production. The lower capacity of inhibition of biofilm 
production by this microorganism might be related with the highest resistance profile of Acinetobacter 
spp. to different antibiotic groups namely, carbapenems (81.2%), observed in Europe [1]. In particular, 
the strain used in the present work is resistant to β-lactamic antibiotics (ampicillin cephalosporins, 
amoxicillin/clavulanic acid) and fosfomycin. 
This is a pioneer study since, as far as we know, there are no reports on the inhibition of biofilm 
production by the studied mushroom extracts and in particular against multi-resistant clinical isolates 
involved in the study; nevertheless, other studies are required to elucidate the mechanism of action. 
Concerning the mechanism of action of phenolic on the inhibition of biofilm, although scarce information 
is available some authors [40–42] demonstrated that phenolic acids may possibly interferer with 
Quorum sensing inhibiting the process of biofilm formation. Sokovic et al. [31], also reported that hot 
water extract from Agaricus blazei could influence on biofilm formation, twitching and swimming 
activity, pyocianin production which are part of anti quorum sensing activity. 
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Table 2. Total phenolic content determined by Folin Ciocalteu-assay and individual phenolic compounds identified by HPLC-DAD (high 
performance liquid chromatography-diode array detection) in the tested wild mushroom extracts (Mean ± SD; n = 3). 
Mushroom 
Phenolics (mg GAE/g 
MWE Extract) 
Protocatechuic 
Acid (mg/kg dw) 
p-Hydroxybenzoic 













 6.31 ± 0.13 a 33.47 ± 0.50 29.31 ± 1.54 b 3.75 ± 0.56 - -  - 
L. giganteus 
3
 6.29 ± 0.20 a - - - - -  - 
M. rosea
3
 3.56 ± 0.37 c na na na na na  na 
R. delica 
3,4
 2.23 ± 0.18 d - - - 0.05  0.11 5.33 0.46 
S. imbricatus 
1
 3.76 ± 0.11 b - 33.19 ± 1.92 a - - -  - 
1 [43]; 2 [44]; 3 [45]; 4 [46]. GAE—gallic acid equivalentes; MWE—metanol:water extract; EE—ethanolic extract; dw—dry weight; na—not available. In each column 
different letters mean significant differences (p < 0.05). 
 
Pathogens 2014, 3 674 
 
 
Overall, the use of biomaterials in several biotechnological applications such as prosthesis, implants, 
urinary and venous catheters, is common in the clinical practice. Otherwise, these biomaterials are 
often colonized by pathogenic microorganisms, which can lead to serious infections and even rejection. 
Therefore, the search and development of new antimicrobial and especially antibiofilm solutions to 
coat these biomaterials conferring them the capacity to avoid the development of these microorganisms 
is crucial. However, the safety of these extracts must be proved to guarantee their safe application as 
antimicrobial or antibiofilm. 
Accordingly, and considering the absence of cytotoxicity of the studied mushroom extracts (tested 
in primary cultures of porcine liver cells), they can be safely incorporated in biomaterials used in catheters, 
prosthesis and other medical devices in order to avoid microorganism adhesion and biofilm production. 
3. Materials and Methods 
3.1. Extracts Preparation 
Each mushroom lyophilized sample (ca. 3 g) was extracted using a methanol:water (80:20; 30 mL) 
mixture at −20 °C for 6 h. After 15 min in an ultrasonic bath, the extract was centrifuged at 4000× g 
for 10 min and filtered through Whatman n° 4 paper. The residue was then extracted with two additional 
30 mL portions of the methanol:water mixture. The combined extracts were evaporated at 40 °C under 
reduced pressure to remove methanol (rotary evaporator Büchi R-210, Flawil, Switzerland), lyophilized, 
redissolved in water, at a concentration of 200 mg/mL, and stored at −20 °C for further use. 
3.2. Bacterial Isolates 
The microorganisms used were the major clinical isolates from patients hospitalized in various 
departments of the Hospital Center of Trás-os-Montes and Alto-Douro, Chaves, Portugal. Thus, four  
Gram-negative bacteria biofilm producers (Escherichia coli, Proteus mirabilis, Pseudomonas 
aeruginosa and Acinetobacter baumannii) isolated from urine were used to verify that extracts of 
Russula delica, Fistulina hepatica, Mycena rosea, Leucopaxilus giganteus and Lepista nuda have the 
ability to inhibit biofilm formation. 
In the case where MIC where found in previous work [28] for the tested extracts (E. coli, P. mirabilis) 
a sub-MIC concentration (half of MIC concentration) was used. In the cases where the MICs are not 
available, the maximal extract concentration (20 mg/mL) was tested, including: all the extracts against 
P. aeruginosa and A. baumannii; Russula delica and Fistulina hepatica against P. mirabilis; and 
Lepista nuda and Mycena rosea against E. coli. 
The isolation and characterization of strains, duly approved by the Ethics Committee, was conducted 
in the CHTMAD (Hospital Center of Trás-os-Montes and Alto-Douro, Chaves, Portugal), which is a 
public institution with 182 beds located in Chaves, North of Portugal. 
3.3. Isolates Identification and Antimicrobial Susceptibility Testing 
Microorganism’s identification and susceptibility tests were performed using MicroScan panels 
(MicroScan
®
; Siemens Medical Solutions Diagnostics, West Sacramento, CA, USA) by microdilution 
plate method. The interpretation criteria were based on Interpretive Breakpoints as indicated in Clinical 
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and Laboratory Standards Institute (CLSI) Document M100-S18 [47] and the report of the Committee 
of L’Antibiogramme de la Société Française de Microbiologie (CA-SFM) [48]. 
3.4. Inhibition of Biofilm Formation 
Quantification of biofilm production was carried out by adapting the microtiter biofilm formation 
protocol described by Stepanovic et al. [49]. Briefly, in a flat bottom 96 microplate, wells were filled 
with 200 μL of test solutions at sub-MIC concentrations (or 20 mg/mL, according section 2.2) with 
inoculum being added at 2% (v/v). Following this the microplate was incubated at 37 °C for 48 h.  
To visualize biofilms, the contents of each well were discarded and the well washed 3 times with sterile 
deionized water in order to remove non-adherent cells. The remaining attached bacteria were fixed 
with 200 μL of ethanol (Panreac, Barcelona, Spain) for 15 min. Ethanol was then discarded and the 
wells air dried. After that, 200 μL of crystal violet solution (Merck, Darmstadt, Germany) were added 
to the wells for 5 min. Excess stain was removed by rinsing the plate under tap water and the air dried. 
Adherence was quantified by measuring the Optical Density (OD) at 660 nm using a microplate 
reader (FlUOstar, OPTIMA, BGM Labtech, Ortenberg, Germany). 
Results for this test were given as percentage of biofilm formation inhibition applying the  
following formula: 
Biofilm formation inhibition percentage = 100 − (ODassay/ODcontrol) x 100 (1) 
All assays were done in triplicate. 
3.5. Toxicity Assay 
A cell culture was prepared from a freshly harvested porcine liver obtained from a local slaughter 
house, and it was designed as PLP2. Briefly, the liver tissues were rinsed in Hank’s balanced salt 
solution containing 100 U/mL penicillin, 100 µg/mL streptomycin and divided into 1 × 1 mm
3
 explants. 
Some of these explants were placed in 25 cm
2
 tissue flasks in DMEM medium supplemented with 10% 
fetal bovine serum, 2 mM nonessential amino acids and 100 U/mL penicillin, 100 mg/mL streptomycin 
and incubated at 37 °C with a humidified atmosphere containing 5% CO2. The medium was changed 
every two days. Cultivation of the cells was continued with direct monitoring every two to three days 
using a phase contrast microscope. Before confluence, cells were subcultured and plated in 96-well 
plates at a density of 1.0 × 10
4
 cells/well, and cultivated in DMEM medium with 10% FBS, 100 U/mL 
penicillin and 100 μg/mL streptomycin. Cells were treated for 48 h with the tested extracts and the 
sulforhodamine B (SRB) colorimetric assay was performed. Briefly, cells were fixed by adding cold 
50% (w/v) trichloroacetic acid (TCA, 25 μL) and incubated for 60 min at 4 °C. Plates were then washed 
with deionized water and dried; SRB solution (0.1% w/v in 1% acetic acid, 50 μL) was then added  
to each plate well and incubated for 30 min at room temperature. Unbound SRB was removed by 
washing with 1% acetic acid. Plates were air-dried and bound stain was solubilized with 100 μL  
of a 100 mM Tris base solution. Optical densities were read on an automated spectrophotometer plate 
reader at a single wavelength of 540 nm (Biotek Elx800, Winooski, VT, USA). Ellipticine was used as 
positive control at a concentration of 5 μM [50]. 
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3.6. Statistical Analysis 
Three samples were used for each species and tested bacteria and all the assays were carried out  
in triplicate for both antibiofilm activity and cell toxicity. The results are expressed as mean values and 
standard deviation (SD). The results were analyzed using one-way analysis of variance (ANOVA) 
followed by Tukey’s HSD Test with α = 0.05. This treatment was carried out using SPSS v. 22.0 
program (IBM Corp., USA). 
4. Conclusions 
The studied mushroom extracts present, in general, good capacity to inhibit biofilm production. 
Among the tested microorganisms, P. aeruginosa seems to be the most susceptible one to the antibiofilm 
activity of the mushroom extracts. It should be highlighted that in some cases where the extract 
concentrations were unable to completely inhibit bacterial growth, the antibiofilm effect was observed. 
Considering that the tested bacteria were clinical isolates with high antibiotic resistance profile, the 
promising results obtained are indeed relevant, so the mechanism of action involved should be further 
studied, in order to clarify the role of mushroom extracts in this dual problematic: multi-resistance and 
high biofilm production. 
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